Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2008

View Archived Issues

Clinical data on besifloxacin in bacterial conjunctivitis reported

Neuronal nicotinic receptor ligands profiled at AstraZeneca

Novel analgesic agents imparted in recent Glenmark, Merck and GSK patents

New therapeutic agents for neurological disorders reported by Taisho and Novartis

Recent Kowa and AstraZeneca patents impart new treatments for respiratory and allergic disorders

Novartis provides update of recent pipeline activity

First-in-human results of NGF enhancer KRX-0501 for the treatment of neurological disorders

PF-00868554 active, well tolerated in double-blind HCV study

Advitech and Laboratoires Urgo sign collaboration agreement in wound healing

HCV candidate BMS-790052 well tolerated in proof-of-concept study

PRT-201 shows potential to improve arteriovenous fistula surgery results

Positive phase III results reported for JZP-6 in fibromyalgia

FDA accepts Vanda's resubmission of NDA for iloperidone

Arpida provides update on iclaprim's regulatory pathway

FDA grants approval to SuperGen to initiate clinical trials of Pim inhibitor SGI-1776

Synta initiates treatment of patients in phase I/II trial of elesclomol in prostate cancer

Biovitrum reports positive results from clinical trial of Sym-001 in HDN

EMEA advises Santhera of negative opinion for idebenone MAA in Friedreich's ataxia

Enrollment suspended following DMC review of phase III MONET trial of motesanib

Aastrom treats first patient in U.S. phase II IMPACT-DCM trial

Takeda submits European MAA for once-daily Competact formulation

Nplate receives positive CHMP opinion for MAA in Europe

RoActemra receives positive opinion in Europe for rheumatoid arthritis

Rasilez HCT receives positive CHMP opinion for treatment of high blood pressure

FDA approves tapentadol immediate-release tablets for acute pain

Invitrogen and Applied Biosystems complete merger

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...